Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation.

Risch, Martin; Weber, Myriam; Thiel, Sarah; Grossmann, Kirsten; Wohlwend, Nadia; Lung, Thomas; Hillmann, Dorothea; Ritzler, Michael; Ferrara, Francesca; Bigler, Susanna; Egli, Konrad; Bodmer, Thomas; Imperiali, Mauro; Salimi, Yacir; Fleisch, Felix; Cusini, Alexia; Renz, Harald; Kohler, Philipp; Vernazza, Pietro; Kahlert, Christian R; ... (2020). Temporal Course of SARS-CoV-2 Antibody Positivity in Patients with COVID-19 following the First Clinical Presentation. BioMed research international, 2020, p. 9878453. Hindawi Publishing Corporation 10.1155/2020/9878453

BMRI2020-9878453.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (910kB) | Preview

Knowledge of the sensitivities of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests beyond 35 days after the clinical onset of COVID-19 is insufficient. We aimed to describe positivity rate of SARS-CoV-2 assays employing three different measurement principles over a prolonged period. Two hundred sixty-eight samples from 180 symptomatic patients with COVID-19 and a reverse transcription polymerase chain reaction (RT-PCR) test followed by serological investigation of SARS-CoV-2 antibodies were included. We conducted three chemiluminescence (including electrochemiluminescence assay (ECLIA)), four enzyme-linked immunosorbent assay (ELISA), and one lateral flow immunoassay (LFIA) test formats. Positivity rates, as well as positive (PPVs) and negative predictive values (NPVs), were calculated for each week after the first clinical presentation for COVID-19. Furthermore, combinations of tests were assessed within an orthogonal testing approach employing two independent assays and predictive values were calculated. Heat maps were constructed to graphically illustrate operational test characteristics. During a follow-up period of more than 9 weeks, chemiluminescence assays and one ELISA IgG test showed stable positivity rates after the third week. With the exception of ECLIA, the PPVs of the other chemiluminescence assays were ≥95% for COVID-19 only after the second week. ELISA and LFIA had somewhat lower PPVs. IgM exhibited insufficient predictive characteristics. An orthogonal testing approach provided PPVs ≥ 95% for patients with a moderate pretest probability (e.g., symptomatic patients), even for tests with a low single test performance. After the second week, NPVs of all but IgM assays were ≥95% for patients with low to moderate pretest probability. The confirmation of negative results using an orthogonal algorithm with another assay provided lower NPVs than the single assays. When interpreting results from SARS-CoV-2 tests, the pretest probability, time of blood draw, and assay characteristics must be carefully considered. An orthogonal testing approach increases the accuracy of positive, but not negative, predictions.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Risch, Lorenz


600 Technology > 610 Medicine & health




Hindawi Publishing Corporation




Karin Balmer

Date Deposited:

23 Nov 2022 07:38

Last Modified:

05 Dec 2022 16:28

Publisher DOI:


PubMed ID:






Actions (login required)

Edit item Edit item
Provide Feedback